Table 2. Clinicopathologic data.
| Total (n=13 918) No. (%)a | 0 nodes (n=9658) No. (%)a | 1 node (n=824) No. (%)a | 2–5 nodes (n=1,202) No. (%)a | 6–10 nodes (n=714) No. (%)a | 11–20 nodes (n=813) No. (%)a | >20 Nodes (n=707) No. (%)a | Chi-square Test P-value | |
|---|---|---|---|---|---|---|---|---|
| Stage of disease | ||||||||
| Stage IIIA | 448 (3.2) | 281 (2.9) | 25 (3.0) | 56 (4.7) | 36 (5.0) | 33 (4.1) | 17 (2.4) | P<0.001 |
| Stage IIIB | 672 (4.8) | 477 (4.9) | 26 (3.2) | 58 (4.8) | 42 (5.9) | 46 (5.7) | 23 (3.3) | |
| Stage IIIC | 4576 (32.9) | 2384 (24.7) | 415 (50.4) | 592 (49.3) | 350 (49.0) | 429 (52.8) | 406 (57.4) | |
| Stage III, NOS | 2366 (17.0) | 2010 (20.8) | 62 (7.5) | 107 (8.9) | 58 (8.1) | 73 (9.0) | 56 (7.9) | |
| Stage IV | 5856 (42.1) | 4506 (46.7) | 296 (35.9) | 389 (32.4) | 228 (31.9) | 232 (28.5) | 205 (29.0) | |
| Grade of disease | ||||||||
| Grade 1 | 580 (4.2) | 366 (3.8) | 30 (3.6) | 47 (3.9) | 43 (6.0) | 47 (5.8) | 47 (6.6) | P=0.005 |
| Grade 2 | 2443 (17.6) | 1684 (17.4) | 135 (16.4) | 211 (17.6) | 123 (17.2) | 164 (20.2) | 126 (17.8) | |
| Grade 3 | 8349 (60.0) | 5673 (58.7) | 531 (64.4) | 765 (63.6) | 437 (61.2) | 490 (60.3) | 453 (64.1) | |
| Unknown | 2546 (18.3) | 1935 (20.0) | 128 (15.5) | 179 (14.9) | 111 (15.5) | 112 (13.8) | 81 (11.5) | |
| Histology | ||||||||
| Serous | 9294 (66.8) | 6474 (67.0) | 553 (67.1) | 805 (67.0) | 457 (64.0) | 532 (65.4) | 473 (66.9) | P<0.001 |
| Endometrioid | 1275 (9.2) | 778 (8.1) | 78 (9.5) | 137 (11.4) | 91 (12.7) | 100 (12.3) | 91 (12.9) | |
| Mucinous | 775 (5.6) | 554 (5.7) | 46 (5.6) | 61 (5.1) | 36 (5.0) | 39 (4.8) | 39 (5.5) | |
| Clear cell | 394 (2.8) | 206 (2.1) | 23 (2.8) | 62 (5.2) | 35 (4.9) | 39 (4.8) | 29 (4.1) | |
| Others or NOS | 2180 (15.7) | 1646 (17.0) | 124 (15.0) | 137 (11.4) | 95 (13.3) | 103 (12.7) | 75 (10.6) | |
a
Percentage of patients for given parameter.